Table 4.
Overview of clinical studies according to the search criteria
| First Author | Year | Tumor: Histology (Origin) |
N | Radiotherapy (Site – Dose [Gy]/ Fractions) |
Immunotherapy | Local response | PFS after response |
|---|---|---|---|---|---|---|---|
| Brinkmann51 | 2005 | RCC (Renal) | 20 | Bone/ Kidney – 45-50 Gy/ 25x | IL-2, IFN-a | 15% CR, 15% PR, 45% SD, 25% PD | NA |
| Jacobs52 | 2005 | Nasopharyngeal Carcinomas | 10 | 70 Gy/35x | IL-2 | Local control 77% | 63% 5 y |
| Seung53 | 2012 | RCC(renal) + Melanoma (skin) | 12 | 60 Gy /3x | IL-2 | LC: 100% M+ | 16 months |
| Barker54 | 2013 | Melanoma | 29 | 30 Gy / 5x | Ipililumab | Local response: 77% | 39 months |
| Abei55 | 2013 | HCC (Hepato Cellular Carcinoma) | 9 | 52.8– 87.6 Gy /22-37x | In situ injection of ‘’CalTUMP’’(BCG extract + hydroxyapatite +microparticulated tuberculin) | Local response: 66% | 6 months |
| Kiess56 | 2015 | Melanoma (Skin) | 46 | Brain – 15-24 Gy/1x | Ipililumab | 1-y LC 87 to100%* | NA |
| Twyman-Saint Victor57 | 2015 | Melanoma Skin) | 22 | 12– 24 Gy/2-3X | Ipililumab | 5% CR; 28% PR; 41% SD; 18% PD – 8% NA | 3.8 months |
| Nardin58 | 2018 | Melanoma Skin) | 74 | Brain | Pembrolizumab | LC: 80% M+ | 4 months |